The use of Fluidda’s FRI technology in the combat against COPD.
The exact prevalence of COPD worldwide is largely unknown, but estimates have varied from 7-19%. The Burden of Obstructive Lung Disease (BOLD) study found a global prevalence of 10.1%.
According to WHO estimates, 65 million people have moderate to severe chronic obstructive pulmonary disease (COPD). More than 3 million people died of COPD in 2005, which corresponds to 5% of all deaths globally. (WHO)
From it’s start in 2005, Fluidda supports both HCP’s as companies who develop new medication for COPD to lighten the burden on COPD patients with their proprietary Functional Respiratory Imaging (FRI) technology.
FRI is a clinically meaningful and non-invasive measurement of the patient-specific respiratory system. A set of distinct biomarkers analyzes exposure, structure and function of the lungs and airways in any respiratory disease included COPD.
Regional information is often crucial to understand the pathophysiology of the individual patient and to give guidance for optimal treatment. Traditional lung function measurements, such as FEV1 or FVC, only provide meaningful information about the condition of the entire lung and do not indicate where the exhaled air is coming from.
The effort of Fluidda in research on COPD resulted so far in 19publications in peer reviewed magazines, a figure that increases rapidly.
Categorised in: Miscellaneous / November 18, 2020 9:31 am /Tags: COPD